We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ProMetic Life Sciences Inc. today announced new clinical data from its ongoing Phase 2 open label clinical trial being conducted in the United Kingdom investigating PBI-4050 for the treatment of patients with Alström syndrome.